Andrea Leonardi
About
In The Last Decade
Andrea Leonardi
177 papers receiving 5.6k citations
Peers
Comparison fields: 5 of 140
- Public Health, Environmental and Occupational Health 4.0k
- Immunology and Allergy 2.2k
- Radiology, Nuclear Medicine and Imaging 1.8k
- Ophthalmology 1.5k
- Immunology 992
Countries citing papers authored by Andrea Leonardi
This map shows the geographic impact of Andrea Leonardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Leonardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Leonardi more than expected).
Fields of papers citing papers by Andrea Leonardi
This network shows the impact of papers produced by Andrea Leonardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Leonardi. The network helps show where Andrea Leonardi may publish in the future.
Co-authorship network of co-authors of Andrea Leonardi
This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Leonardi. A scholar is included among the top collaborators of Andrea Leonardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Leonardi. Andrea Leonardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 2 | |
| 5 | 2 | |
| 6 | Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients With Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials | 1 |
| 7 | 66 | |
| 8 | Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study | 1 |
| 9 | 19 | |
| 10 | 13 | |
| 11 | 1 | |
| 12 | The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion | 1 |
| 13 | 1 | |
| 14 | 4 | |
| 15 | A New Clinical Grading of Vernal Keratoconjunctivitis: A Classification-Regression Tree (cart®) Analysis | 0 |
| 16 | Histamine H1R, H2R, H3R and H4R Receptors in Normal Conjunctiva and in Vernal Keratoconjunctivitis | 1 |
| 17 | Differences in Cytokine Pattern Production in Adults and Children With Vernal Keratoconjunctivitis | 2 |
| 18 | Release of Hyaluronic Acid From Filcon1b Contact Lens Increases Tolerability and Performance | 2 |
| 19 | Metalloproteases, Cytokines and Growth Factors Detection in Tears of Vernal Keratoconjunctivitis (VKC) Patients by Antibody Array Analysis | 1 |
| 20 | NONSTEROIDAL ANTIINFLAMMATORY DRUGS AFTER EXCIMER LASER PHOTOREFRACTIVE KERATECTOMY (PRK):A RANDOMIZED DOUBLE BLIND STUDY | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.